{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-029125","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.127908+00:00","generated_at":"2026-05-15T00:15:20.943241+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance","bullets":["Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).","Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.","Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.","Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.","Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029125","json":"https://secwatch.observer/filing/0001628280-26-029125.json","markdown":"https://secwatch.observer/filing/0001628280-26-029125.md","text":"https://secwatch.observer/filing/0001628280-26-029125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/irmd-20260501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:15:20.943241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eedf8bb42dd11e31773597044a01f176fc08c4e9","claim":"IRADIMED CORP reported first quarter of 2026 results: revenue revenue of $22.0 million, net income net income of $5.8 million, EPS $0.45 per diluted share. Guidance reaffirmed.","evidence_excerpt":"IRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance • Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. • Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"revenue of $22.0 million"},{"label":"Net income","value":"net income of $5.8 million"},{"label":"EPS","value":"$0.45 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}